Ocular Therapeutix cuts 13% of workforce, 37 jobs, to prioritize AXPAXLI

OCULAR THERAPEUTIX, INC

Board approved reduction in force of 37 employees (~13% of workforce), mainly in R&D and technical operations.
Action taken to focus resources on AXPAXLI (axitinib intravitreal implant) for wet AMD clinical development.
Expects total restructuring costs of $1.0 to $2.0 million for severance and related costs in Q2/Q3 2024.
Reduction expected to be substantially completed in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.